J
Joanna Jozwiak
Researcher at Leipzig University
Publications - 6
Citations - 209
Joanna Jozwiak is an academic researcher from Leipzig University. The author has contributed to research in topics: Gap junction & Connexin. The author has an hindex of 5, co-authored 6 publications receiving 191 citations.
Papers
More filters
Journal ArticleDOI
Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides
Stefan Dhein,Anja Hagen,Joanna Jozwiak,Anna Dietze,Jens Garbade,Markus J. Barten,Martin Kostelka,Friedrich-Wilhelm Mohr +7 more
TL;DR: Antiarrhythmic peptides are effective against ventricular tachyarrhythmias, such as late ischaemic ventricular fibrillation, CaCl2 or aconitine-induced arrhythmia, and it is still a matter of debate whether these drugs also act against atrialfibrillation.
Journal ArticleDOI
Remodeling of cardiac passive electrical properties and susceptibility to ventricular and atrial arrhythmias
Stefan Dhein,Thomas Seidel,Aida Salameh,Joanna Jozwiak,Anja Hagen,Martin Kostelka,Gerd Hindricks,Friedrich-Wilhelm Mohr +7 more
TL;DR: The present review elucidates the implications of passive electrical properties for cardiac rhythm and arrhythmogenesis, and suggests a balanced geometrical distribution of gap junctions and reduced gap junction conductance may allow successful propagation of electrical impulse propagation.
Journal ArticleDOI
Local effects and mechanisms of antiarrhythmic peptide AAP10 in acute regional myocardial ischemia: electrophysiological and molecular findings.
Joanna Jozwiak,Stefan Dhein +1 more
TL;DR: In the ischemic area, AAP10 prevents from ischemia-induced CX43 dephosphorylation and loss of Cx43 from the gap junction at cell poles and in parallel prevents the decrease in ARI homogeneity and attenuates ischemIA-induced slowing of activation wave propagation.
Journal ArticleDOI
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.
Michael Kühl,Christian Binner,Joanna Jozwiak,Julia Fischer,Jochen Hahn,Alaeldin Addas,B. Dinov,Jens Garbade,Gerhard Hindricks,Michael A. Borger +9 more
TL;DR: This study demonstrates that the PCSK9 inhibitors Evolocumab and Alirocumab lead to a significant reduction of LDL Cholesterol in heart transplantation recipients, with no effect on cardiac function or episodes of rejections.
Journal ArticleDOI
Desipramine prevents cardiac gap junction uncoupling
Joanna Jozwiak,Anna Dietze,Rajiv Grover,Alex Savtschenko,Christian D. Etz,Friedrich W. Mohr,Stefan Dhein +6 more
TL;DR: In isolated hearts, ischemia resulted in significantly increased dispersion of activation–recovery intervals, loss of membrane Cx43, and dephosphorylation of CX43, which all could be prevented by desipramine.